skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

ML-1 is one of three celll lines isolated in 1978 from the peripheral blood of a 24 year old male patient with acute myeloblastic leukaemia. The cells can convert to more mature cells by the use of DMSO. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.


Tissue of Origin


DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,11
D5S818: 12
D7S820: 9,11
D13S317: 9,12
D16S539: 9,12
TH01: 7,9.3
TPOX: 8,10
vWA: 16


Not specified


Tumourigenicity and biochemical studies


Myelogenous Leukaemia

Culture Conditions

Cell Type


Subculture Routine

Maintain cultures between 2-9x100,000 cells/ml; 5% CO₂; 37°C. Freeze in 10% DMSO + 90% FBS. Immediately after resuscitation, pellet cells by centrifugation at 150 x g for 5 minutes and resuspend the cell pellet in fresh medium. This is to remove the presence of DMSO which may cause differentiation of the cells if allowed to remain.

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Growth Mode


Additional Info


Dr D Flavell, Southampton General Hospital,

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2



Ohyashiki K, Ohyashiki JH, Sandberg AA 1986 Cytogenetic characterization of putative human myeloblastic leukemia cell lines (ML-1, -2, and -3): origin of the cells. Cancer Res. 46(7):3642-7 PMID: 3458526.


Herrmann R, Han T, Barcos MP, Lok MS, Henderson ES 1980 Malignant lymphoma of pre-T-cell type terminating in acute myelocytic leukemia. A case report with enzymic and immunologic marker studies. Cancer. 46(6):1383-8 PMID: 6998554. Takeda K, Minowada J, Bloch A. 1982 Kinetics of appearance of differentiation-associated characteristics in ML-1, a line of human myeloblastic leukemia cells, after treatment with 12-O-tetradecanoylphorbol-13-acetate, dimethyl sulfoxide or 1-beta-D-arabinofuranosylcytosine. Cancer Res. 42(12):5152-8.PMID: 6958361. Teyssier JR 1989 The chromosomal analysis of human solid tumors. A triple challenge. Cancer Genet Cytogenet. 37(1):103-25 PMID: 2645045.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: ML-1 (ECACC 88113007).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.